Myeloid-derived suppressor cells-immunotherapy targets in hematological malignancies
10.3760/cma.j.issn.1673-422X.2017.04.020
- VernacularTitle:髓源性抑制细胞——血液肿瘤的免疫治疗靶点
- Author:
Jingjing LIU
;
Caibao JIN
;
Xiuwen XU
;
Xiaojian ZHU
;
Li MENG
- Keywords:
Immunosuppressive agents;
Therapy;
Myeloid-derived suppressor cells
- From:
Journal of International Oncology
2017;44(4):313-316
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the research hot in the field of solid tumor and blood tumor focuses on the myeloid-derived suppressor cells (MDSCs).In tumors, MDSCs not only exert immunosuppression by inhibiting T cell proliferation, destroying the functions of natural killer cells and recruiting regulatory T cells, but also play non-immunosuppression roles in the promotion of angiogenesis and tumor metastasis.All of these hinder the anti-tumor therapy, and particularly affect the curative effect, which are related with a poor clinical prognosis.MDSCs can be used as prognostic markers, which provide new targets for immunotherapy.
